Startups
Even the most promising vaccines don’t always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine development.
We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies.
As an established independent CDMO in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials in humans.
Part of Utrecht Science Park Bilthoven
We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies.
As an established independent CDMO in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials in humans.
Part of Utrecht Science Park Bilthoven
Overview
Location
Netherlands, Utrecht, Bilthoven
Employees
51-200
Founded date
2013
Mentions in press and media 15
Show more
Reviews 0
FAQ about Intravacc
When was Intravacc founded?
Intravacc was founded in 2013.
What has the press written about Intravacc?
Parsers VC has collected 15 articles mentioning Intravacc, among them “Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections” (Jan 16, 2024) and “Amsterdam-based cancer vaccine biotech startup CimCure raises €5M” (Jun 8, 2022).
Is Intravacc still active?
Yes, Intravacc is active; its latest activity on Parsers VC dates from Oct 13, 2025.